The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Congressionally Directed Medical Research Programs -- Peer Reviewed Alzheimer’s Disease Research Program -- Convergence Science Research Award
The PRARP Convergence Science Research Award (CSRA) mechanism was first offered in FY12. Since then, 195 CSRA applications have been received, and 36 have been recommended for funding.
The intent of the FY17 PRARP CSRA is to support efforts to generate research resources, tools, or novel research efforts for researchers and/or practitioners in health sciences related to the PRARP’s mission (see Section II.A, Program Description).
The FY17 PRARP CSRA is open to Principal Investigators (PIs) at or above the level of Assistant Professor (or equivalent) from any field or discipline. As part of the application, the PI should demonstrate that the study team has experience in both TBI and AD/ADRD research. Preliminary data, while not required, are encouraged. Preliminary data may come from the PI’s published work, pilot data, or from peer-reviewed literature.
- REQUIRED Pre-application Submission Deadline: September 21, 2017 (was September 6, 2017)
- Full Application Submission Deadline: October 5, 2017 (was September 20, 2017)
Areas of Interest
FY17 PRARP CSRA Overarching Challenges: This FY17 PRARP CSRA funding opportunity requires applications to address one or more of the following FY17 PRARP CSRA Overarching Challenges:
• Paucity of Research Resources: The paucity of research resources to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities.
• Paucity of Clinical Studies: The paucity of clinical studies to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI.
• Diagnostic Technologies, Tests, Biomarkers or Devices: The need for technologies, tests, or devices to detect or prognose the progression to AD/ADRD subsequent to TBI. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI.
• Epidemiology: The paucity of epidemiological research to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI.
FY17 PRARP CSRA Focus Areas: In addition to addressing one or more of the specified FY17 PRARP CSRA Overarching Challenges, applications should address at least one of the following FY17 PRARP CSRA Focus Areas in support of the FY17 PRARP CSRA Overarching Challenges. An application that proposes research outside of the FY17 PRARP CSRA Focus Areas is acceptable, as long as the applicant provides a strong rationale:
• Genomics/Proteomics: Studies or technologies (e.g., genetic, proteomic, bioinformatics and epigenetic strategies) intended to characterize neurological change(s) associated with TBI and subsequent AD/ADRD. In addition, relevant technologies or tests may be considered under this focus area.
• Mechanisms of Pathogenesis: Identification of contributing mechanisms (e.g., pathology of Tau, non-neuronal cells, inflammatory factors, and vascular contributions) associated with TBI and subsequent AD/ADRD pathogenesis.
• Biomarkers: Development of strategies to diagnose, prognose, or characterize neurological changes or risk factors associated with TBI and subsequent AD/ADRD (e.g., fluid-based, imaging, physiological, and clinical approaches).
• Novel Target Identification: Basic research (non-human) directly leading to identification of new targets for the development of existing or new investigational medicines, drugs, or agents.
• Epidemiological Research: Research focusing on the incidence, distribution, and other factors relating to the health of individuals affected by TBI and subsequent AD/ADRD.
The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).
Each investigator may submit only one FY17 PRARP CSRA application as a PI.
The anticipated direct costs budgeted for the entire period of performance for an FY17 PRARP CSRA will not exceed $500,000. The maximum period of performance is 3 years. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.